1. Home
  2. PBYI vs SANG Comparison

PBYI vs SANG Comparison

Compare PBYI & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • SANG
  • Stock Information
  • Founded
  • PBYI 2010
  • SANG 1984
  • Country
  • PBYI United States
  • SANG Canada
  • Employees
  • PBYI N/A
  • SANG N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • SANG Computer Software: Programming Data Processing
  • Sector
  • PBYI Health Care
  • SANG Technology
  • Exchange
  • PBYI Nasdaq
  • SANG Nasdaq
  • Market Cap
  • PBYI 153.2M
  • SANG 235.6M
  • IPO Year
  • PBYI N/A
  • SANG 2021
  • Fundamental
  • Price
  • PBYI $3.09
  • SANG $7.01
  • Analyst Decision
  • PBYI Strong Buy
  • SANG
  • Analyst Count
  • PBYI 1
  • SANG 0
  • Target Price
  • PBYI $7.00
  • SANG N/A
  • AVG Volume (30 Days)
  • PBYI 754.5K
  • SANG 7.6K
  • Earning Date
  • PBYI 02-27-2025
  • SANG 02-06-2025
  • Dividend Yield
  • PBYI N/A
  • SANG N/A
  • EPS Growth
  • PBYI 492.79
  • SANG N/A
  • EPS
  • PBYI 0.47
  • SANG N/A
  • Revenue
  • PBYI $243,569,000.00
  • SANG $244,406,000.00
  • Revenue This Year
  • PBYI N/A
  • SANG $3.36
  • Revenue Next Year
  • PBYI N/A
  • SANG $7.39
  • P/E Ratio
  • PBYI $6.63
  • SANG N/A
  • Revenue Growth
  • PBYI 6.30
  • SANG N/A
  • 52 Week Low
  • PBYI $2.23
  • SANG $2.50
  • 52 Week High
  • PBYI $7.73
  • SANG $7.20
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.17
  • SANG 57.08
  • Support Level
  • PBYI $2.92
  • SANG $6.89
  • Resistance Level
  • PBYI $4.06
  • SANG $7.15
  • Average True Range (ATR)
  • PBYI 0.29
  • SANG 0.20
  • MACD
  • PBYI 0.01
  • SANG -0.02
  • Stochastic Oscillator
  • PBYI 27.07
  • SANG 51.28

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

Share on Social Networks: